GlassScriptPhysician profile
Muhammad Anwaar
NPI 1295345965
$9,113.26
in general payments reported to CMS, 2019-2025
10 companies · $6,301 in 2025
The $6,301 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $21.38 · 2024: $2,791 · 2025: $6,301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,087 · Food and Beverage: $3,627 · Grant: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,086.53 |
| Food and Beverage | $3,626.73 |
| Grant | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,756.44 | 2024-2025 | Watchman Access System, Ekosonic, General - Catheter |
| Penumbra, INC. | $3,330.56 | 2024-2025 | Indigo System, Ruby Coil, Penumbra System |
| Abiomed | $736.31 | 2025 | |
| Medtronic, INC. | $638.10 | 2025 | Corevalve Evolut R, Azure Xt Dr Mri Surescan, Omniasecure Mri Surescan |
| Edwards Lifesciences Corporation | $299.01 | 2023-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Amgen INC. | $119.92 | 2024-2025 | Repatha, Repatha |
| Abbott Laboratories | $98.97 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.57 | 2024 | Jardiance |
| Novo Nordisk INC | $50.00 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $21.38 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Anwaar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.